Impacts of BRCA mutations and clinical factors on niraparib efficacy in patients with platinum-sensitive recurrent ovarian cancer: a retrospective study
BRCA mutations, CA125 levels, FIGO staging, BMI, and platinum sensitivity are critical factors influencing the efficacy of niraparib in PSROC patients. These findings have provided valuable insights into the individualized application of niraparib and the optimization of treatment strategies for PSROC patients.
Authors
- Zheyu Hu
Institutions
- University of South China (CN)
Publication Details
- Journal
- American Journal of Cancer Research
- Published
- 2025-01-01
- DOI
- https://doi.org/10.62347/fgly8019
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00